Healthcare / Medical Care FacilitiesMilan
$0.66
+0.05 (+7.32%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 11%
FCF escenarios
weak_data · normalized FCF $436000.00 · quality 25.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$15M
P/E
N/A
•EV/EBITDA
12.8x
↑ROE
-2.6%
↓Gross Margin
95.4%
↑Debt/Equity
4.44
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.0%
FCF CAGR
-24.9%
FCF margin
0.8%
FCF / Net income
-0.58x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $52.9M · net income $-749000.0 · FCF $436000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $52.9M | $52.9M | $51.7M | $49.5M | $47.0M |
| Net Income | $-749000.00 | $-749000.00 | $-524000.00 | $556000.00 | $443000.00 |
| EBITDA | $11.2M | $11.2M | $12.3M | $12.4M | $10.9M |
| EPS | — | — | -0.02 | 0.02 | 0.02 |
| Gross Margin | 95.4% | 95.4% | 94.7% | 94.4% | 94.5% |
| Operating Margin | 10.2% | 10.2% | 9.8% | 10.5% | 8.2% |
| Net Margin | -1.4% | -1.4% | -1.0% | 1.1% | 0.9% |
| Balance Sheet | |||||
| Debt/Equity | 4.44 | 4.44 | 3.32 | 3.54 | 3.79 |
| Current Ratio | 0.21 | 0.21 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $436000.00 | $436000.00 | $-13.1M | $3.6M | $1.0M |
| Returns | |||||
| ROE | -2.6% | -2.6% | -1.8% | 1.9% | 1.5% |
| Valuation | |||||
| P/E | — | — | — | 38.93 | 63.85 |
| EV/EBITDA | 12.79 | 12.79 | 9.21 | 10.09 | 12.52 |
| P/B | 0.52 | 0.52 | 0.60 | 0.72 | 0.96 |
| Growth & Yield | |||||
| Revenue Growth | 2.4% | 2.4% | 4.5% | 5.1% | — |
| EPS Growth | — | — | -194.7% | 25.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-16.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → n/d
Residual
-16.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.